TransCode shareholders reject reverse stock split; stock plan amendment approved

Transcode Therapeutics, Inc.

Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
Stock plan amendment passed: 526,212 for, 205,773 against; adds 3,000,000 shares for issuance.
All four director nominees elected (Calais, Fitzgerald, Manting, Marquet) with ~595K-597K votes for.
Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.